1 / 5

Multiple Myeloma Therapeutics in Asia-Pacific Market worth 2.8 Billion by 2020

Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. The disease is incurable; although over the past decade there have been significant improvements in therapy, driven by a greater understanding of pathophysiology.

MIR114
Download Presentation

Multiple Myeloma Therapeutics in Asia-Pacific Market worth 2.8 Billion by 2020

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Multiple Myeloma Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Velcade, Revlimid and Emerging Supplementary Treatments Published on – 01 October, 2015 | Number of pages : 117 Single User Price: $4995 “Over the 2014–2020 forecast period, the MM market in Australia, China, India and Japan is expected to increase in value at a CAGR of 7.4%, from $1.7 billion to about $2.8 billion. ”

  2. Summary of the Report:Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. The disease is incurable; although over the past decade there have been significant improvements in therapy, driven by a greater understanding of pathophysiology. MM represents about 0.8–1% of all cancer cases worldwide and approximately 10% of all hematological cancers, with incidence rates ranging from 0.4 to 5 per 100,000 persons in different parts of the world. Without any treatment, the median survival of a myeloma patient is about six months, but this can be extended with the use of various forms of treatment. There are now five classes of drugs used in the treatment of myeloma: immunomodulatory drugs, chemotherapy, proteasome drugs, Histone Deacetylase (HDAC) inhibitors and steroids. Many of the notable drugs in these classes were approved over the past 10–15 years. Treatment using these novel drugs and high-dose chemotherapy with hematopoietic Stem-Cell Transplant (SCT) has been shown to improve median survival to five years, which makes this the current standard therapy. However, many patients suffer relapse or develop treatment resistance, leaving a need to develop safe and effective treatments that prolong the duration of remission and improve survival. Click Here To Check Complete Report

  3. Scope of the Report: • The different segments of patients with MM are based on their eligibility for an SCT • What combination therapies are used for various segments? • What are the treatment options available for myeloma, providing an overview of the front-line, second-line and third-line therapies available? • What are the dominant mechanisms of action across marketed products? • Which products are approved currently in each country and which ones are likely to be launched within the forecast period? • Which product is used more in each country? • Will there be any label expansions of existing market leaders in any of the countries? • Epidemiology of MM is significantly different in Asia-Pacific countries from that in the major markets. • What are the various epidemiology trends in each country? • What factors contribute to the overall epidemiology? • Which class is most prominent within the pipeline? • Do the pipeline molecules offer an advantage over commercially proven mechanisms? • What are the late-pipeline products expected to be launched in each country in the near future? Download Sample Brochure

  4. Reasons to buy: • This report will enable you to - • Understand the clinical context of MM by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options. • Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need. • Consider market opportunities and potential risks by examining trends in clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action. • Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential by examining clinical trial data and multi-scenario product forecast projections. • Compare treatment usage patterns, annual therapy costs, and market growth projections for India, China, Australia and Japan. • Discover trends in licensing and co-development deals concerning MM products and identify the major strategic consolidations that have shaped the commercial landscape. Make an Inquiry Before Buying

  5. Multiple Myeloma Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Velcade, Revlimid and Emerging Supplementary Treatments A detailed qualitative analysis of the factors responsible for driving and restraining growth of the Multiple Myeloma Therapeutics Market are provided in the report. Contact: 1-302-684-6088 sales@marketintelreports.com www.marketintelreports.com Click here to order a copy of Multiple Myeloma Therapeutics Market Report

More Related